U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07711418) titled 'A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients >= 12 Years of Age With Moderate-to-Severe Atopic Dermatitis' on July 14.
Brief Summary: This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo.
The estimated participant overall duration is approximately 15 months.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Moderate-to-Severe Atopic Dermatitis
Intervention:
DRUG: Rezpegaldesleukin
Pharmaceutical form: Inje...